Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherTOXICOLOGY

Development and Characterization of a New Model of Tacrine-Induced Hepatotoxicity: Role of the Sympathetic Nervous System and Hypoxia-Reoxygenation

Robert F. Stachlewitz, Gavin E. Arteel, James A. Raleigh, Henry D. Connor, Ronald P. Mason and Ronald G. Thurman
Journal of Pharmacology and Experimental Therapeutics September 1997, 282 (3) 1591-1599;
Robert F. Stachlewitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gavin E. Arteel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James A. Raleigh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry D. Connor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald P. Mason
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald G. Thurman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Tacrine is an acetylcholinesterase inhibitor approved for the treatment of Alzheimer’s disease. Unfortunately, reversible hepatotoxicity in about 30% of patients at therapeutic doses limits clinical use. The purpose of this study was to develop and characterize a model of tacrine hepatotoxicity to begin to understand the mechanisms of injury. Rats were given tacrine (10–50 mg/kg, intragatrically) and killed 24 hr later. An increase in serum aspartate aminotransferase was observed up to 35 mg/kg and histology revealed pericentral necrosis and fatty changes. Aspartate aminotransferase was increased from 12 to 24 hr and returned to control values by 32 hr. Livers were perfused in a nonrecirculating system to measure oxygen uptake and trypan blue was infused at the end of each experiment to evaluate tissue perfusion. Time for trypan blue to distribute evenly throughout the liver 3 hr after tacrine treatment was significantly increased (6.9 ± 1.3 min) compared to controls (1.0 ± 0.3 min) reflecting decreased tissue perfusion. Tacrine also significantly increased the binding of a hypoxia marker, pimonidazole, in pericentral regions almost 3-fold, and increased portal pressure in vivo significantly. It is hypothesized that tacrine, by inhibiting acetylcholine breakdown in the celiac ganglion, increases sympathetic activity in the liver leading to vascular constriction, hypoxia and liver injury. To test this hypothesis, the hepatic nerve was severed and animals were allowed to recover before tacrine treatment. This procedure significantly reduced serum aspartate aminotransferase, time of dye distribution, pimonidazole binding and portal pressure. Furthermore, a free radical adduct was detected with spin trapping and electron spin resonance spectroscopy 8 hr after tacrine treatment, providing evidence for reoxygenation. When catechin (100 mg/kg, i.p.), a free radical scavenger, was given before tacrine, injury was decreased by about 45%. Furthermore, feeding 5% arginine in the diet significantly reduced portal pressure and time of dye distribution. These data are consistent with the hypothesis that tacrine hepatotoxicity is a hypoxia-reoxygenation injury mediated through the sympathetic nervous system.

Footnotes

  • Send reprint requests to: Dr. Ronald G. Thurman, CB# 7365, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365.

  • ↵1 This work was supported, in part, by a grant from NIH (ES-04325), a generous gift from Parke-Davis and a traineeship to R.S. (GM- 07040–2).

  • Abbreviations:
    AST
    aspartate aminotransferase
    4-POBN
    α-(4-pyridyl-1-oxide)-N-tert-butylnitrone
    ESR
    electron spin resonance
    • Received January 10, 1997.
    • Accepted May 23, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 3
1 Sep 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Development and Characterization of a New Model of Tacrine-Induced Hepatotoxicity: Role of the Sympathetic Nervous System and Hypoxia-Reoxygenation
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherTOXICOLOGY

Development and Characterization of a New Model of Tacrine-Induced Hepatotoxicity: Role of the Sympathetic Nervous System and Hypoxia-Reoxygenation

Robert F. Stachlewitz, Gavin E. Arteel, James A. Raleigh, Henry D. Connor, Ronald P. Mason and Ronald G. Thurman
Journal of Pharmacology and Experimental Therapeutics September 1, 1997, 282 (3) 1591-1599;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherTOXICOLOGY

Development and Characterization of a New Model of Tacrine-Induced Hepatotoxicity: Role of the Sympathetic Nervous System and Hypoxia-Reoxygenation

Robert F. Stachlewitz, Gavin E. Arteel, James A. Raleigh, Henry D. Connor, Ronald P. Mason and Ronald G. Thurman
Journal of Pharmacology and Experimental Therapeutics September 1, 1997, 282 (3) 1591-1599;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cutaneous PAO Exposure as a Model for Lewisite-Induced ALI
  • Time-dependent manner in vancomycin sensitivity underlie AKI
  • High dose acetaminophen with concurrent CYP2E1 inhibition
Show more Toxicology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics